Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Liao, Guixiang; Zhao, Zhihong; Qian, Yuting; Ling, Xiean; Chen, Shanyi; Li, Xianming; Kong, Feng-Ming Spring

Liao, Guixiang; Zhao, Zhihong; Qian, Yuting; Ling, Xiean; Chen, Shanyi; Li, Xianming; Kong, Feng-Ming Spring.

Afiliação

Liao G; Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
Zhao Z; Department of Nephrology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
Qian Y; Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
Ling X; Department of Thoracic Surgery, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
Chen S; Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
Li X; Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
Kong FS; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Front Oncol ; 11: 774131, 2021.

Article em En | MEDLINE | ID: mdl-35004295

Palavras-chave

immune checkpoint inhibitors; immunotherapy; non-small cell lung cancer; overall survival; prognosis; soluble programmed death ligand 1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google